RESUMEN

Rabies virus as a neurotropic agent causes rabies in humans and animals. Rabies virus transmission usually occurs through direct contact with saliva of rabid animals. However, serological and molecular tests commonly are used in diagnosing rabies but all the detection methods of rabies have some limitations. It is necessary to develop a rapid, effective, and low-cost biosensor as an alternative tool to detect rabies virus. In this review, we studied related biosensor researches to rabies virus detection for comparing it with other detection test including serological and molecular methods. Given that very limited studies have been conducted in this field, biosensors as quick, effective, and high sensitivity tools can be used in diagnostic of rabies as an alternative tool instead of other detection methods. According to the important role of rapid detection of rabies in the control of infection and public health measures, development of a biosensor as a quick tool can be very significant in the diagnosis of rabies.

Asunto(s)

Técnicas Biosensibles , Virus de la Rabia , Rabia , Animales , Humanos , Rabia/diagnóstico , Rabia/prevención & control

RESUMEN

Abstract Hypoxia-inducible factors (HIFs) and cancer stem cells (CSCs) are two challenging causes of radiotherapy and chemotherapy resistance, leading to most cases of failure and recurrence in breast cancer therapy. This study was conducted to investigated the inhibitory effect of combination therapy with doxorubicin (an anthracycline) and FM19G11 (an HIF inhibitor) on MCF-7 cells and their CSC-like cells (CSC-LCs). MCF-7 CSC-LCs with a CD44+/CD24- phenotype were sorted and characterized by flow cytometry. A combination of doxorubicin and FM19G11 caused more cytotoxic effects on MCF-7 and CSC-LCs compared to doxorubicin monotherapy. The largest synergistic effect was observed in CSC-LCs under hypoxic conditions; however, MCF-7 cells showed no synergism in normoxic conditions. The administration of doxorubicin and FM19G11 induced late apoptotic and necrotic cell death in MCF-7 and CSC-LCs. Additionally, G2 phase arrest was observed in both cells. Our results demonstrated that co-administration of FM19G11 and doxorubicin had a synergistic effect in hypoxia and improved drug resistance in breast cancer stem cells.